ClinicalTrials.gg
CompletedNCT03014648Updated Dec 13, 2023Results posted

Evaluating the Efficacy of Atezolizumab in Advanced Non-small Cell Lung Cancer (NSCLC)

A Phase 2 interventional study of Atezolizumab in Advanced Non-small Cell Lung Cancer, sponsored by Liza Villaruz, MD. Completed at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-12-13.

Sponsored by Liza Villaruz, MD · Phase 2, Interventional, and Treatment

How we know · 3 judgments

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
28
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 81 studies testing atezolizumab in Carcinoma, Non-Small-Cell Lung — 13 open to participants now, 27 under way, 5 of them phase 3. atezolizumab · Carcinoma, Non-Small-Cell Lung.

Enrollment
62nd of 81
28 · median 80
Started
2017
with 7 others
Phase 2
48 of 81
8 open now
Registered
23rd of 81
by date
Lead sponsor
2 of 81
Liza Villaruz, MD

Among the 81 studies testing atezolizumab in Carcinoma, Non-Small-Cell Lung, this one is the 62nd largest by enrollment, is one of 8 that started in 2017, is one of 48 in phase 2, and was the 23rd registered.

Carcinoma, Non-Small-Cell Lung

7,639 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

13 of the 81 studies testing atezolizumab in Carcinoma, Non-Small-Cell Lung are open now, in 6 countries. Recruiting first, the newest first:

8 more — sign in →

By country, each count listing its studies:

All 13 open studies →

About atezolizumab

atezolizumab: first FDA approval 2016 (TECENTRIQ), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,324 Carcinoma, Non-Small-Cell Lung studies recruiting now, 987 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 81 studies testing atezolizumab in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

This is a phase II clinical trial aimed at evaluating the efficacy of PD-L1 inhibition with atezolizumab in advanced squamous and non-squamous NSCLC patients previously treated with anti-PD-1 therapy with either nivolumab or pembrolizumab.

In order to account for the variability of response kinetics to PD-1 directed therapy, patients will be enrolled in 3 parallel cohorts based on the best overall response to PD-1 directed therapy.

  • Cohort 1 (progressive disease)
  • Cohort 2 (stable disease with minimum 12 weeks of therapy)
  • Cohort 3 (partial to complete response followed by progressive disease)
Read the detailed description

Atezolizumab will be given on day 1 of a 21-day cycle at 1200 mg IV. Radiographic assessments for disease response will occur every 6 weeks while on treatment. Confirmatory scans should be obtained ≥ 4 weeks following initial documentation of objective response or progressive disease on atezolizumab therapy.

Atezolizumab will be given as long as the patient continues to experience clinical benefit in the opinion of the investigator or until unacceptable toxicity, symptomatic deterioration attributed to disease progression.

Patients will be followed for 12 months or until death as per standard of care after discontinuation of Atezolizumab or until death, whichever occurs first.

03

Conditions studied

  • Advanced Non-small Cell Lung Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with Stage IIIB/IV squamous or non-squamous NSCLC (American Joint Committee on Cancer 7th Edition Staging) who have had prior treatment with nivolumab or pembrolizumab will be enrolled in one of 3 parallel cohorts based on the following:

    • Cohort 1: Patient with progressive disease on nivolumab or pembrolizumab as the best overall response. Progressive disease must be confirmed with a confirmatory scan ≤ 4 weeks after the 1st documented date of progression.
    • Cohort 2: Patients with stable disease as the best overall response on a minimum of 12 weeks of therapy with nivolumab or pembrolizumab.
    • Cohort 3: Patients with partial or complete response as the best overall response followed by progressive disease, on nivolumab or pembrolizumab. A confirmatory scan at the time of disease progression must be performed ≤ 4 weeks after the 1st documented date of progression.
  • Both men and women of all races and ethnic groups are eligible for this trial
  • Patients must have resolution of toxic effects to Grade 1 or less from prior therapy (except alopecia).
  • Patients must sign Form and show ability and willingness to comply with the requirements of the study protocol.
  • 18 years of age or older
  • Willingness to undergo a ≤ 6 weeks of the start of study treatment to obtain formalin-fixed paraffin-embedded tumor specimens in paraffin blocks (blocks are preferred) or at least 15 unstained slides, with an associated pathology report, for central testing of tumor expression.
  • Adequate hematologic and end organ function, defined by the following laboratory results obtained within 14 days prior to the first study treatment (Cycle 1, Day 1):

    • ANC equal to/greater than 1500 cells/µL
    • WBC counts greater than 2500/µL
    • Lymphocyte count equal to/greater than 300µ/L
    • count equal to/greater than 100,000/µL
    • equal to/greater than 9.0 g/dL
    • Total equal to/less than 1.5 x with the following exception:

      • Patients with known Gilbert disease who have serum bilirubin level equal to/less than 3 x ULN may be enrolled.
    • and ALT equal to/less than 3.0 x ULN with the following exception:

      • Patients with liver involvement: AST and/or ALT equal to/less than 5 x ULN
    • Alkaline phosphatase equal to/less than 2.5 x ULN with the following exception:

      • Patients with documented liver involvement or bone : alkaline phosphatase equal to/less than 5 x ULN
  • Serum creatinine equal to/less than 1.5 x ULN or equal to/greater than 50 mL/min on the basis of the Cockcroft-Gault estimation.
  • per v1.1 for patients with solid .
  • For female patients of and male patients with partners of childbearing potential, agreement (by patient and/or partner) to use highly effective form(s) of (i.e., one that results in a low failure rate [less than 1% per year] when used consistently and correctly) and to continue its use for 5 months after the last dose of Atezolizumab.
  • Performance Status of 0 or 1. Patients with an ECOG Performance Status of 2 will be allowed at the discretion of the Treating Investigator in agreement with the Sponsor-Investigator.
  • and aPTT equal to/less than 1.5 x ULN. This applies only to patients who do not receive therapeutic anticoagulation; patients receiving therapeutic anticoagulation (such as low-molecular-weight heparin or warfarin) should be on a stable dose.

Exclusion criteria

Exclusion Criteria:

  • Any approved anticancer therapy, including chemotherapy, hormonal therapy, or radiotherapy, within 3 weeks prior to initiation of study treatment; however, the following are allowed:

    • Hormone-replacement therapy or oral .
    • Herbal therapy greater than 1 week prior to Cycle 1, Day 1 (herbal therapy intended as anticancer therapy must be discontinued at least 1 week prior to Cycle 1, Day 1).
    • Hormonal therapy for prostate cancer or breast cancer provided criteria in 3.2.21 are met.

      • Palliative radiotherapy (e.g., treatment of known bony ) allowed, provided it does not interfere with the assessment of tumor target lesions (e.g. the lesion being irradiated is not the only site of disease, because that would render the patient not evaluable for response by tumor assessments according to v1.1).
  • Adverse events from prior anticancer therapy that have not resolved to Grade equal to/less than1 except for alopecia.
  • History of grade 4 immune-related adverse events requiring treatment with prednisone or history of grade 3 immune-related adverse events requiring prednisone >10 mg/kg for >12 weeks.
  • Bisphosphonate therapy for symptomatic hypercalcemia (use of bisphosphonate therapy for other reasons (e.g., bone metastasis or osteoporosis) is allowed).
  • Known liver disease, including active viral, alcoholic, or other hepatitis; cirrhosis; fatty liver; and inherited liver disease.
  • Patients with acute leukemias, accelerated/blast phase chronic myelogenous leukemia, chronic lymphocytic leukemia, Burkitt lymphoma, plasma cell leukemia, or non-secretory myeloma.
  • Known primary central nervous system (CNS) or symptomatic . Patients with asymptomatic untreated CNS disease may be enrolled, provided all of the following criteria are met:

    • Evaluable or outside the CNS.
    • No metastases to brain stem, midbrain, pons, medulla, cerebellum, or within 10 mm of the optic apparatus (optic nerves and chiasm).
    • No history of intracranial hemorrhage or spinal cord hemorrhage.
    • No ongoing requirement for dexamethasone for CNS disease; patients on a stable dose of anticonvulsants are permitted.
    • No neurosurgical resection or brain within 28 days prior to Cycle 1, Day 1.
  • Patients with asymptomatic treated CNS metastases may be enrolled, provided all the criteria listed above are met as well as the following:

    • Radiographic demonstration of improvement upon the completion of CNS directed therapy and no evidence of interim progression between the completion of CNS-directed therapy and the screening radiographic study.
    • No stereotactic radiation or whole-brain radiation within 28 days prior to Cycle 1, Day 1.
    • Screening CNS radiographic study equal to/greater than 4 weeks from completion of radiotherapy and equal to/greater than 2 weeks from discontinuation of .
  • Patients who are pregnant, are lactation, or breastfeeding.
  • Known to Chinese hamster ovary cell products or other recombinant human antibodies.
  • Inability to comply with study and follow-up procedures.
  • History or risk of disease, including but not limited to systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, vascular thrombosis associated with antiphospholipid syndrome, Wegener's granulomatosis, Sjögren's syndrome, Bell's palsy, Guillain-Barré syndrome, multiple sclerosis, autoimmune thyroid disease, vasculitis, or glomerulonephritis.

    • Patients with a history of autoimmune hypothyroidism on a stable dose of thyroid replacement hormone may be eligible.
    • Patients with controlled Type 1 diabetes mellitus on a stable insulin regimen may be eligible.
    • Patients with eczema, psoriasis, lichen simplex chronicus of vitiligo with dermatologic manifestations only (e.g., patients with psoriatic arthritis would be excluded) are permitted provided that they meet the following conditions:
    • Patients with psoriasis must have a baseline ophthalmologic exam to rule out ocular manifestations.
    • Rash must cover less than 10% of body surface area (BSA).
    • Disease is well controlled at baseline and only requiring low potency topical steroids (e.g., hydrocortisone 2.5%, hydrocortisone butyrate 0.1%, fluocinolone 0.01%, desonide 0.05%, alclometasone dipropionate 0.05%).
    • No acute exacerbations of underlying condition within the last 12 months (not requiring psoralen plus ultraviolet A radiation [PUVA], methotrexate, retinoids, biologic agents, oral calcineurin inhibitors; high potency or oral steroids).
  • History of idiopathic pulmonary fibrosis, pneumonitis (including drug induced), organizing pneumonia (i.e., bronchiolitis obliterans, cryptogenic organizing pneumonia, etc.), or evidence of active pneumonitis on screening chest computed tomography (CT) scan. History of radiation pneumonitis in the radiation field (fibrosis) is permitted.
  • Any other diseases, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an drug or that may affect the interpretation of the results or render the patient at high risk from treatment complications.
  • History of infection or active (chronic or acute) or infection.

    • Patients with past or resolved hepatitis B infection (defined as having a negative hepatitis B surface antigen [HBsAg] test and a positive anti-HBc [antibody to hepatitis B core antigen] antibody test) are eligible.
    • Patients positive for hepatitis C virus (HCV) antibody are eligible only if polymerase chain reaction (PCR) is negative for HCV RNA.
  • Active tuberculosis.
  • Severe infections within 4 weeks prior to Cycle 1, Day 1, including but not limited to hospitalization for complications of infection, bacteremia, or severe pneumonia.
  • Signs or symptoms of infection within 2 weeks prior to Cycle 1, Day 1.
  • Received oral or IV antibiotics within 2 weeks prior to Cycle 1, Day 1. Patients receiving prophylactic antibiotics (e.g., for prevention of a urinary tract infection or ) are eligible.
  • Major surgical procedure within 28 days prior to Cycle 1, Day 1 or anticipation of need for a major surgical procedure during the course of the study.
  • Administration of a live, attenuated vaccine within 4 weeks before enrollment or anticipation that such a will be required during the study or for 5 months after the last dose of Atezolizumab. Influenza vaccination should be given during influenza season only (approximately October to March). Patients must not receive live, attenuated influenza vaccine (e.g., FluMist) within 4 weeks prior to enrollment, at any time during the study, or for 5 months after the last dose of Atezolizumab.
  • Malignancies other than the disease under study within 5 years prior to Cycle 1, Day 1, with the exception of those with a negligible risk of metastasis or death and with expected curative outcome (such as adequately treated carcinoma in situ of the cervix, basal or squamous cell skin cancer, localized prostate cancer treated surgically with curative intent, or ductal carcinoma in situ treated surgically with curative intent) or undergoing active surveillance per standard-of-care management (e.g., chronic lymphocytic leukemia Rai Stage 0, prostate cancer with Gleason score equal to/less than 6, and prostate-specific antigen equal to/less than10 mg/mL, etc.).
  • Treatment with investigational agent within 4 weeks prior to Cycle 1, Day 1 (or within five half lives of the investigational product, whichever is longer).
  • Treatment with systemic medications (including but not limited to prednisone, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor [anti-TNF] agents) within 2 weeks prior to Cycle 1, Day 1.

    • Patients who have received acute, low dose, systemic immunosuppressant medications (e.g., a one-time dose of dexamethasone for nausea) may be enrolled.
    • The use of inhaled corticosteroids and mineralocorticoids (e.g., fludrocortisone) for patients with orthostatic hypotension or adrenocortical insufficiency is allowed.
  • History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins.
  • Patients with prior bone marrow transplantation or prior solid organ transplantation.
Terms in these criteria, in plain language(31)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
28 participants (actual)

Study arms

  • Experimental
    Atezolizumab

    Atezolizumab will be given on day 1 of a 21-day cycle at 1200 mg IV over 60 (plus or minus 15) minutes for first infusion; can be decreased to 30 (plus or minus 10) minutes for subsequent cycles. Atezolizumab will be given as long as the patient continues to experience clinical benefit in the opinion of the investigator or until unacceptable toxicity, symptomatic deterioration attributed to disease progression. There will be no dose reduction for Atezolizumab. Patients may temporarily suspend study treatment for up to 84 days beyond the scheduled date of delayed infusion if study drug-related toxicity requiring dose suspension is experienced. If Atezolizumab is held because of adverse events for greater than 84 days beyond the scheduled date of infusion, the patient will be discontinued from Atezolizumab and will be followed for safety and efficacy.

    Drug: Atezolizumab

Interventions

  • Atezolizumab will be administered through an IV over 60 minutes at a dose of 1200mg on Day 1 of each 21-day cycle. If the first dose is tolerated without any infusion-related adverse events, the following doses can be administered over 30 minutes.

    Also known as: Tecentriq

06

What researchers measure

Primary outcomes

  1. Best Overall Response (BOR)

    Best response recorded is recorded from the start of the treatment until disease progression/recurrence (taking as reference for progressive disease the smallest measurements recorded since the treatment started). Per RECIST v1.1: Complete Response (CR) - Disappearance of all target lesions. Any pathological lymph nodes (target or non-target) with reduction in short axis to \<10 mm. Partial Response (PR): ≥30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.

    Time frame: Approximately 53.5 months

Secondary outcomes

  1. Duration of Response (DOR)

    The length of time that a tumor continues to respond to treatment from first documentation of response until disease progression.Per RECISIt v1.1: Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (target or non-target) with reduction in short axis to \<10 mm. Partial Response (PR): ≥30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study. Progressive Disease (PD):≥20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). The sum must also demonstrate an absolute increase of ≥5 mm. The appearance ≥1 new lesion(s) is considered progression.

    Time frame: Approximately 56.5 months

  2. Progression-free Survival (PFS)

    The length of time during and after treatment that a patient lives with disease but without disease progression. Per RECISIT v1.1: Progressive Disease (PD):≥20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). The sum must also demonstrate an absolute increase of ≥5 mm. The appearance ≥1 new lesion(s) is considered progression.

    Time frame: Approximately 56.5 months

  3. 6-month Progression-free Survival (PFS)

    The number of patients alive without disease progression at 6 months, per RECIST v1.1. Progressive Disease (PD):≥20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). The sum must also demonstrate an absolute increase of ≥5 mm. The appearance ≥1 new lesion(s) is considered progression.

    Time frame: Up to 6 months

  4. 12-month Progression-free Survival (PFS)

    The number of patients alive without disease progression at 12 months, per RECIST v1.1. Progressive Disease (PD):≥20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). The sum must also demonstrate an absolute increase of ≥5 mm. The appearance ≥1 new lesion(s) is considered progression.

    Time frame: Up to 12 months

  5. 24-month Progression-free Survival (PFS)

    The number of patients alive without disease progression at 24 months, per RECIST v1.1. Progressive Disease (PD):≥20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). The sum must also demonstrate an absolute increase of ≥5 mm. The appearance ≥1 new lesion(s) is considered progression.

    Time frame: Up to 24 months

  6. Overall Survival (OS)

    The length of time from start of treatment that patients remain still alive.

    Time frame: Approximately 56.5 months

  7. 6-month Overall Survival (OS)

    The number of participants alive at 6 months.

    Time frame: Up to 6 months

  8. 12-month Overall Survival (OS)

    The number of patients alive at 12 months.

    Time frame: Up to 12 months

  9. 24-month Overall Survival (OS)

    The number of patients alive at 24 months.

    Time frame: Up to 24 months

  10. Adverse Events ≥ Grade 3

    Number of patients that experienced grade 3 or greater Adverse events per the Cancer Therapy Evaluation Program (CTEP) Common Terminology Criteria for Adverse Events (CTCAE) version 4, determined to be at least possibly, probably or definitely related to treatment, or that result in dose holds or reductions, will be collected and reported. Grade 3 = Severe AE and Grade 4 = Life-threatening or disabling AE. Adverse events and serious adverse events will be tabulated in order of prevalence, with the highest grade reported by each patient.

    Time frame: Approximately 56.5 months

Other outcomes

  1. PD-L1 Expression

    PD-L1 protein expression will be measured as positive (present) or negative (absent) in tissue from a biopsy conducted after discontinuation of the prior therapy and before initiation of study drug.

    Time frame: Up to 6 years

07

Results

Posted Dec 13, 2023

Participant flow

Participant flow — Overall Study
MilestoneAtezolizumab
Started28
Completed28
Not completed0

Outcome measures

PrimaryBest Overall Response (BOR)

Best response recorded is recorded from the start of the treatment until disease progression/recurrence (taking as reference for progressive disease the smallest measurements recorded since the treatment started). Per RECIST v1.1: Complete Response (CR) - Disappearance of all target lesions. Any pathological lymph nodes (target or non-target) with reduction in short axis to \<10 mm. Partial Response (PR): ≥30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.

Time frame:
Approximately 53.5 months
Reported as:
Count of participants · Participants
Best Overall Response (BOR)
ParticipantsCR/PR CohortSD CohortPD Cohort
Progressive Disease229
Partial Response101
Stable Disease415
Unknown001
SecondaryDuration of Response (DOR)

The length of time that a tumor continues to respond to treatment from first documentation of response until disease progression.Per RECISIt v1.1: Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (target or non-target) with reduction in short axis to \<10 mm. Partial Response (PR): ≥30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study. Progressive Disease (PD):≥20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). The sum must also demonstrate an absolute increase of ≥5 mm. The appearance ≥1 new lesion(s) is considered progression.

Time frame:
Approximately 56.5 months
Reported as:
Number · months
Duration of Response (DOR)
monthsCR/PR CohortPD Cohort
Duration of Response (DOR)60
SecondaryProgression-free Survival (PFS)

The length of time during and after treatment that a patient lives with disease but without disease progression. Per RECISIT v1.1: Progressive Disease (PD):≥20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). The sum must also demonstrate an absolute increase of ≥5 mm. The appearance ≥1 new lesion(s) is considered progression.

Time frame:
Approximately 56.5 months
Reported as:
Median · months
Progression-free Survival (PFS)
monthsCR/PR CohortSD CohortPD Cohort
Progression-free Survival (PFS)4.00 (2.00 to 9.00)2.00 (1.00 to NA)2.00 (1.00 to 4.00)
Secondary6-month Progression-free Survival (PFS)

The number of patients alive without disease progression at 6 months, per RECIST v1.1. Progressive Disease (PD):≥20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). The sum must also demonstrate an absolute increase of ≥5 mm. The appearance ≥1 new lesion(s) is considered progression.

Time frame:
Up to 6 months
Reported as:
Count of participants · Participants
6-month Progression-free Survival (PFS)
ParticipantsCR/PR CohortSD CohortPD Cohort
6-month Progression-free Survival (PFS)302
Secondary12-month Progression-free Survival (PFS)

The number of patients alive without disease progression at 12 months, per RECIST v1.1. Progressive Disease (PD):≥20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). The sum must also demonstrate an absolute increase of ≥5 mm. The appearance ≥1 new lesion(s) is considered progression.

Time frame:
Up to 12 months
Reported as:
Count of participants · Participants
12-month Progression-free Survival (PFS)
ParticipantsCR/PR CohortSD CohortPD Cohort
12-month Progression-free Survival (PFS)101
Secondary24-month Progression-free Survival (PFS)

The number of patients alive without disease progression at 24 months, per RECIST v1.1. Progressive Disease (PD):≥20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). The sum must also demonstrate an absolute increase of ≥5 mm. The appearance ≥1 new lesion(s) is considered progression.

Time frame:
Up to 24 months
Reported as:
Count of participants · Participants
24-month Progression-free Survival (PFS)
ParticipantsCR/PR CohortSD CohortPD Cohort
24-month Progression-free Survival (PFS)101
SecondaryOverall Survival (OS)

The length of time from start of treatment that patients remain still alive.

Time frame:
Approximately 56.5 months
Reported as:
Median · months
Overall Survival (OS)
monthsCR/PR CohortSD CohortPD Cohort
Overall Survival (OS)7.00 (2.00 to NA)11.00 (3.00 to NA)6.00 (4.00 to 11.00)
Secondary6-month Overall Survival (OS)

The number of participants alive at 6 months.

Time frame:
Up to 6 months
Reported as:
Count of participants · Participants
6-month Overall Survival (OS)
ParticipantsCR/PR CohortSD CohortPD Cohort
6-month Overall Survival (OS)428
Secondary12-month Overall Survival (OS)

The number of patients alive at 12 months.

Time frame:
Up to 12 months
Reported as:
Count of participants · Participants
12-month Overall Survival (OS)
ParticipantsCR/PR CohortSD CohortPD Cohort
12-month Overall Survival (OS)313
Secondary24-month Overall Survival (OS)

The number of patients alive at 24 months.

Time frame:
Up to 24 months
Reported as:
Count of participants · Participants
24-month Overall Survival (OS)
ParticipantsCR/PR CohortSD CohortPD Cohort
24-month Overall Survival (OS)101
SecondaryAdverse Events ≥ Grade 3

Number of patients that experienced grade 3 or greater Adverse events per the Cancer Therapy Evaluation Program (CTEP) Common Terminology Criteria for Adverse Events (CTCAE) version 4, determined to be at least possibly, probably or definitely related to treatment, or that result in dose holds or reductions, will be collected and reported. Grade 3 = Severe AE and Grade 4 = Life-threatening or disabling AE. Adverse events and serious adverse events will be tabulated in order of prevalence, with the highest grade reported by each patient.

Time frame:
Approximately 56.5 months
Reported as:
Count of participants · Participants
Adverse Events ≥ Grade 3
ParticipantsCR/PR CohortSD CohortPD Cohort
Diarrhea100
Fatigue100
Infusion related reaction100
Lipase increased001
Serum amylase increased001
Generalized muscle weakness001
Other pre-specifiedPD-L1 Expression

PD-L1 protein expression will be measured as positive (present) or negative (absent) in tissue from a biopsy conducted after discontinuation of the prior therapy and before initiation of study drug.

Time frame:
Up to 6 years

Results for this outcome have not been posted.

Adverse events

Collected over Approximately 56.5 months. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
CR/PR Cohort8/8 (100%)3/8 (37.5%)8/8 (100%)
SD Cohort3/3 (100%)1/3 (33.3%)3/3 (100%)
PD Cohort17/17 (100%)13/17 (76.5%)17/17 (100%)
Most frequent serious events
Showing 10 of 37
Most frequent serious events
EventCR/PR CohortSD CohortPD Cohort
Lung infectionInfections and infestations3/80/33/17
HypothyroidismEndocrine disorders0/81/30/17
DyspneaRespiratory, thoracic and mediastinal disorders2/80/34/17
NauseaGastrointestinal disorders0/80/33/17
Atrial fibrillationCardiac disorders1/80/30/17
Colonic perforationGastrointestinal disorders1/80/30/17
DiarrheaGastrointestinal disorders1/80/30/17
Infusion related reactionGeneral disorders1/80/30/17
PainGeneral disorders1/80/32/17
Abdominal infectionInfections and infestations1/80/30/17
Most frequent other events
Showing 10 of 136
Most frequent other events
EventCR/PR CohortSD CohortPD Cohort
AnemiaBlood and lymphatic system disorders6/81/311/17
FatigueGeneral disorders4/81/39/17
Sinus tachycardiaCardiac disorders4/81/33/17
Lymphocyte count decreasedInvestigations4/80/32/17
Activated partial thromboplastin time prolongedInvestigations4/80/34/17
AnorexiaMetabolism and nutrition disorders4/80/34/17
NauseaGastrointestinal disorders2/80/38/17
ConstipationGastrointestinal disorders3/80/35/17
Urinary tract infectionInfections and infestations3/80/30/17
Weight lossInvestigations3/80/31/17

Baseline characteristics

Patients with advanced non-small cell lung cancer (NSCLC) patients previously treated with PD-1-directed therapy, treated with atezolizumab.

Age, Continuous
Age, Continuous(years)CR/PR CohortSD CohortPD CohortTotal
Mean73.50 ± 6.6565.67 ± 13.6566.41 ± 10.5968.5 ± 10.3
Sex: Female, Male
Sex: Female, Male(Participants)CR/PR CohortSD CohortPD CohortTotal
Female53715
Male301013
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)CR/PR CohortSD CohortPD CohortTotal
Hispanic or Latino0000
Not Hispanic or Latino0022
Unknown or Not Reported831526
Race (NIH/OMB)
Race (NIH/OMB)(Participants)CR/PR CohortSD CohortPD CohortTotal
American Indian or Alaska Native0000
Asian0011
Native Hawaiian or Other Pacific Islander0000
Black or African American0213
White811524
More than one race0000
Unknown or Not Reported0000
Histology
Histology(Participants)CR/PR CohortSD CohortPD CohortTotal
ADENOCARCINOMA IN SITU, NOS0011
ADENOCARCINOMA, METASTATIC, NOS2035
ADENOCARCINOMA, N/A0011
ADENOCARCINOMA, NOS431017
LARGE CELL CARCINOMA, METASTATIC1001
NON-SMALL CELL CA0011
SQUAMOUS CELL CA METASTATIC, NOS0011
SQUAMOUS CELL CARCINOMA, NOS1001
08

Study locations

2 sites
  • AdventHealth Orlando
    Orlando, Florida 32804, United States
  • UPMC Hillman Cancer Center
    Pittsburgh, Pennsylvania 15232, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2017 to primary completion in Dec 2021, 53 months.

Results were first posted in Dec 2023, 1 year 11 months after primary completion.

Of 732 non-industry phase 2 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 84. This study's 53 months is close to that.

Counting every sponsor, half of 1,049 studies reached it within 48 months; a quarter within 30 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 29, 2016
First posted
Jan 9, 2017
StartActual
Jul 18, 2017
Primary completionActual
Dec 31, 2021
CompletionActual
Mar 31, 2022
Results first posted
Dec 13, 2023
Last update
Dec 13, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 13, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03014648
Lead sponsor
Liza Villaruz, MD
Collaborators
Genentech, Inc.
Responsible party
Liza Villaruz, MD (Assistant Professor of Medicine, University of Pittsburgh) — Sponsor-investigator
First posted
Jan 9, 2017
Start date
Jul 18, 2017
Primary completion
Dec 31, 2021
Completion
Mar 31, 2022
Results posted
Dec 13, 2023
Last update
Dec 13, 2023

Study contacts

Liza Villaruz, MD
principal investigator · University of Pittsburgh Medical Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Atezolizumab

Start the discussion